In November 2024, Senwo International's Doha office was officially established, marking a new phase in its strategic layout within the Middle East's pharmaceutical sector. As a healthcare hub in the Middle East, Doha, with its free zone policies (100% foreign ownership and tax exemption periods) and support for biomedicine under the "2030 National Vision," has become a core pivot for Senwo to expand its regional market.
Leveraging Qatar's "2030 National Vision" support for local pharmaceutical production, the company will facilitate the transfer of international innovative drug manufacturing technologies to the Middle East, covering key technologies such as biologics purification processes and aseptic filling. It provides comprehensive one-stop services from plant design, cleanroom engineering, equipment installation to factory operations. The company has already signed contracts for biopharmaceutical construction projects in Qatar’s free zones. On the operational side, it will handle GMP compliance management, capacity optimization, production, and supply chain coordination for factories, planning to undertake multiple local pharmaceutical plant operation orders within two years.
In recent years, Qatar has been the fastest-growing country in Middle Eastern healthcare investment for three consecutive years, offering full-chain support for R&D and production to foreign enterprises through its free zone policies. This move by Senwo not only responds to the trend of China-UAE pharmaceutical cooperation but also aligns with cross-border investment and financing mechanisms promoted jointly with international capital. In the future, the Doha branch will serve as a base to reach out to core markets such as Saudi Arabia and the UAE, contributing to the Middle East's goal of achieving pharmaceutical self-reliance by 2050.
Copyright © 2025 Senwo International
